ACoA: Rethinking APS with the Guidance of New Classification Criteria
Nov 14, 2023
auto_awesome
Award-winning researcher, Dr. Doruk Erkan, discusses new classification criteria for Antiphospholipid Syndrome (APS), highlighting the challenges of diagnosis and the need for further research. The podcast explores the complexity of APS, emphasizes the importance of assessing the antiphospholipid antibody profile, and discusses the limitations of the old criteria. The development of the new classification criteria is discussed, emphasizing the collaborative effort and point-based system. The podcast also touches on the challenges of APS guidelines, the development of criteria for patients needing anticoagulation, and the potential impact on diagnosis and management of ANIFOSFELIPIT syndrome.
The newly published classification criteria for Antiphospholipid Syndrome (APS) aim to provide a more accurate and specific classification, addressing the systemic nature of APS and including risk stratification and clear definitions of clinical and laboratory domains.
Further research is needed to better define Antiphospholipid Syndrome (APS), including the study of different APL profiles and clinical phenotypes, in order to enhance the understanding and management of the disease.
Deep dives
The Importance of New Classification Criteria for APS
The podcast episode discusses the development of the 2023 ACR-ULAR Classification Criteria for Antiphospholipid Syndrome (APS). The episode highlights the need for new criteria due to the limitations of the old Sapporo criteria. The new criteria aim to provide a more accurate and specific classification of APS, allowing for a homogeneous population for research purposes. It also addresses the systemic nature of APS and includes risk stratification and clear definitions of clinical and laboratory domains. The strengths of the new criteria include high specificity, better risk stratification, and the ability to update individual domains as needed.
Understanding Antiphospholipid Syndrome (APS)
The podcast delves into the definition and understanding of Antiphospholipid Syndrome (APS). It explains that APS is a systemic autoimmune disease characterized by thrombotic obstetric and non-thrombotic clinical problems, all caused by autoimmune antiphospholipid antibodies. The speaker emphasizes the importance of considering the syndrome's concurrence of symptoms and the varying ways in which antiphospholipid antibodies may develop or cause symptoms. The discussion highlights the need for further research to better define APS, including the study of different APL profiles and clinical phenotypes.
Manifestations of APS and Challenges in Diagnosis
The podcast explores the diverse manifestations of Antiphospholipid Syndrome (APS) in different organ systems. It covers venous and arterial thrombosis, obstetric complications, microvascular disease, and non-thrombotic problems related to antiphospholipid antibodies. The speaker emphasizes the importance of considering different vascular beds affected by APS and when to suspect APS based on the organs or tissues involved. The challenges of diagnosing APS, particularly the interpretation of antiphospholipid antibody levels, are discussed, highlighting the need for careful assessment and consideration of additional risk factors.
Overview of the New Classification Criteria
The podcast provides an overview of the new 2023 ACR-ULAR Classification Criteria for APS. It explains that these criteria are point-based and allow for classification based on a cumulative score. At least three points from clinical domains and at least three points from laboratory domains are required for APS classification. The episode highlights the strengths of the criteria, including the incorporation of risk stratification, clear definitions, and the ability to update individual domains as needed. It also mentions the desire for future research to further validate and refine the criteria and enhance the understanding and management of APS.
Award-winning researcher, Dr. Doruk Erkan joins us today with newly published classification criteria for Antiphospholipid Syndrome (APS). Dr. Erkan joins us today with those criteria and why he believes there is sufficient evidence to “Rethink APS”.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode